{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:49:52Z","timestamp":1786988992897,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"am","delay-in-days":527,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.euf.2024.09.007","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T15:48:52Z","timestamp":1726933732000},"page":"150-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma"],"prefix":"10.1016","volume":"11","author":[{"given":"Emily","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Rupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar S.","family":"Mukhida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amado J.","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.09.007_b0005","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2024.09.007_b0010","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s40265-021-01606-x","article-title":"Belzutifan: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.euf.2024.09.007_b0015","unstructured":"Welireg (belzutifan) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2021."},{"key":"10.1016\/j.euf.2024.09.007_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.v8i2.170","article-title":"Hypoxia-inducible factor-2\u03b1 as a novel target in renal cell carcinoma","volume":"8","author":"Choi","year":"2021","journal-title":"J Kidney Cancer VHL"},{"key":"10.1016\/j.euf.2024.09.007_b0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.euf.2024.09.007_b0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/cancers16030601","article-title":"Novel approaches with HIF-2\u03b1 targeted therapies in metastatic renal cell carcinoma","volume":"16","author":"Nguyen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euf.2024.09.007_b0035","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1200\/JCO.2024.42.16_suppl.4513","article-title":"Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2\u03b1 inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma","volume":"42","author":"Pal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.09.007_b0040","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1158\/1078-0432.CCR-23-3029","article-title":"A first-in-human phase 1 study of a tumor-directed RNA-interference drug against HIF2\u03b1 in patients with advanced clear cell renal cell carcinoma","volume":"30","author":"Brugarolas","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.09.007_b0045","doi-asserted-by":"crossref","first-page":"S1329","DOI":"10.1016\/j.annonc.2023.10.090","article-title":"Belzutifan versus everolimus in participants (Pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase II LITESPARK-005 study","volume":"34","author":"Albiges","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2024.09.007_b0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2024.09.007_b0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamaoncol.2021.4337","article-title":"Treatment selection in first-line metastatic renal cell carcinoma\u2014the contemporary treatment paradigm in the age of combination therapy: a review","volume":"8","author":"Navani","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4_suppl","key":"10.1016\/j.euf.2024.09.007_b0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2024.42.4_suppl.406","article-title":"Evolving metastatic renal cell carcinoma (mRCC) treatment landscape in the post vascular endothelial growth factor (VEGF) and immune checkpoint inhibitor (IO) setting","volume":"42","author":"Shah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.09.007_b0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11864-022-00966-0","article-title":"Reshaping treatment paradigms for advanced renal cell cancer patients and improving patient management: optimal management for renal cell cancer patients","volume":"23","author":"Cetin","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.euf.2024.09.007_b0070","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2024.09.007_b0075","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/oncolo\/oyae037","article-title":"Efficacy, safety, and tolerability of tivozanib in heavily pretreated patients with advanced clear cell renal cell carcinoma","volume":"29","author":"Johns","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.euf.2024.09.007_b0080","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/onco.13770","article-title":"Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies","volume":"26","author":"Wiele","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.euf.2024.09.007_b0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41581-022-00544-5","article-title":"Belzutifan: a novel therapy for von Hippel-Lindau disease","volume":"18","author":"Zhou","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.euf.2024.09.007_b0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924001755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924001755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:26:05Z","timestamp":1762622765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924001755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2405456924001755"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.09.007","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}